Basma M Sharaf1, Alexander D Giddey2, Hasan Alniss1,3, Hamza M Al-Hroub3, Raafat El-Awady1,3, Muath Mousa4, Ahmed Almehdi4,5, Nelson C Soares6,3, Mohammad H Semreen7,3. 1. College of Pharmacy, University of Sharjah, Sharjah, United Arab Emirates. 2. Department of Integrative Biomedical Sciences, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa. 3. Sharjah Institute for Medical Research, University of Sharjah, Sharjah, United Arab Emirates. 4. Research Institute of Science and Engineering, University of Sharjah, Sharjah, United Arab Emirates. 5. Department of Chemistry, College of Sciences, University of Sharjah, Sharjah, United Arab Emirates. 6. College of Pharmacy, University of Sharjah, Sharjah, United Arab Emirates; nsoares@sharjah.ac.ae. 7. College of Pharmacy, University of Sharjah, Sharjah, United Arab Emirates; msemreen@sharjah.ac.ae.
Abstract
BACKGROUND/AIM: Trastuzumab and tamoxifen are two of the most widely prescribed anti-cancer drugs for breast cancer (BC). To date, few studies have explored the impact of anticancer drugs on metabolic pathways in BC. Metabolomics is an emerging technology that can identify new biomarkers for tracking therapy response and novel therapeutic targets. MATERIALS AND METHODS: We employed ultra-high-performance liquid chromatography-quadrupole time of flight mass spectrometry (UHPLC-QTOF-MS) to investigate changes in MCF-7 and SkBr3 cell lines treated with either tamoxifen, trastuzumab or a combination of both. The Bruker Human Metabolome Database (HMDB) metabolite library was used to match spectra and the MetaboScape software to assign each feature with a putative metabolite name or molecular formula for metabolite annotation. RESULTS: A total of 98 metabolites were found to significantly differ in abundance in MCF-7 and SkBr3 treated cells. Moreover, the metabolic profile of the combination medication is similar to that of tamoxifen alone, according to functional enrichment analysis. CONCLUSION: Tamoxifen/trastuzumab treatment had a significant effect on pathways essential for the control of energy-production, which have previously been linked to cancer progression, and aggressiveness.
BACKGROUND/AIM: Trastuzumab and tamoxifen are two of the most widely prescribed anti-cancer drugs for breast cancer (BC). To date, few studies have explored the impact of anticancer drugs on metabolic pathways in BC. Metabolomics is an emerging technology that can identify new biomarkers for tracking therapy response and novel therapeutic targets. MATERIALS AND METHODS: We employed ultra-high-performance liquid chromatography-quadrupole time of flight mass spectrometry (UHPLC-QTOF-MS) to investigate changes in MCF-7 and SkBr3 cell lines treated with either tamoxifen, trastuzumab or a combination of both. The Bruker Human Metabolome Database (HMDB) metabolite library was used to match spectra and the MetaboScape software to assign each feature with a putative metabolite name or molecular formula for metabolite annotation. RESULTS: A total of 98 metabolites were found to significantly differ in abundance in MCF-7 and SkBr3 treated cells. Moreover, the metabolic profile of the combination medication is similar to that of tamoxifen alone, according to functional enrichment analysis. CONCLUSION: Tamoxifen/trastuzumab treatment had a significant effect on pathways essential for the control of energy-production, which have previously been linked to cancer progression, and aggressiveness.
Authors: Alexander J Muller; James B DuHadaway; P Scott Donover; Erika Sutanto-Ward; George C Prendergast Journal: Nat Med Date: 2005-02-13 Impact factor: 53.440
Authors: Fatima Obeidat; Mamoun Ahram; Ali Al Khader; Khairat Battah; Mohammad Alchalabi; Jamal Masad Melhem; Ahmad Suleiman Journal: J Pak Med Assoc Date: 2017-08 Impact factor: 0.781
Authors: Greta Carioli; Matteo Malvezzi; Teresa Rodriguez; Paola Bertuccio; Eva Negri; Carlo La Vecchia Journal: Breast Date: 2017-12-13 Impact factor: 4.380
Authors: Andy J Minn; Gaorav P Gupta; David Padua; Paula Bos; Don X Nguyen; Dimitry Nuyten; Bas Kreike; Yi Zhang; Yixin Wang; Hemant Ishwaran; John A Foekens; Marc van de Vijver; Joan Massagué Journal: Proc Natl Acad Sci U S A Date: 2007-04-09 Impact factor: 11.205
Authors: Leen Oyoun Alsoud; Nelson C Soares; Hamza M Al-Hroub; Muath Mousa; Violet Kasabri; Nailya Bulatova; Maysa Suyagh; Karem H Alzoubi; Waseem El-Huneidi; Bashaer Abu-Irmaileh; Yasser Bustanji; Mohammad H Semreen Journal: Metabolites Date: 2022-06-01